Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (61571202)
- National Institute of Allergy and Infectious Diseases (AI157106)
- University of Texas MD Anderson Cancer Center
- Baylor College of Medicine
- National Institute of General Medical Sciences (GM124724)
This publication has 72 references indexed in Scilit:
- Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatmentCell, 2023
- Mutual interaction between gut microbiota and protein/amino acid metabolism for host mucosal immunity and healthAnimal Nutrition, 2021
- Clp is a “busy” transcription factor in the bacterial warrior, Lysobacter enzymogenesComputational and Structural Biotechnology Journal, 2021
- Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint InhibitorsEuropean Urology, 2020
- Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma PatientsEuropean Urology, 2020
- Inter-kingdom signaling between gut microbiota and their hostCellular and Molecular Life Sciences, 2019
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma PatientsNeoplasia, 2017
- Manipulation of the Quorum Sensing Signal AI-2 Affects the Antibiotic-Treated Gut MicrobiotaCell Reports, 2015
- The Integrative Human Microbiome Project: Dynamic Analysis of Microbiome-Host Omics Profiles during Periods of Human Health and DiseaseCell Host & Microbe, 2014
- Sporulation of Bacillus subtilisCurrent Opinion in Microbiology, 2004